OKYO Pharma Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert J. Dempsey
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Park Lane London GL United Kingdom W1K 1NA
- IPO Date
- May 17, 2022
- CIK
- 0001849296
- Website
- okyopharma.com
- Similar Companies
- Business
- OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops novel G protein-coupled receptor (GPCR)-targeted therapeutics for inflammatory eye diseases including dry eye disease, neuropathic corneal pain, uveitis and allergic conjunctivitis; its lead product candidate urcosimod (formerly OK-101), a membrane-anchored chemerin receptor (ChemR23/CMKLR1) agonist and non-opioid analgesic, is in Phase 2 trials for neuropathic corneal pain (initiated Q3 2024) and has completed Phase 2 for dry eye disease (Q4 2023) with positive long-term stability data; the company advances preclinical programs for urcosimod in uveitis and allergic conjunctivitis, alongside OK-201, an agonist for MAS-Related G Protein-Coupled Receptor (MRGPR) targeting acute and chronic ocular pain via novel topical and nasal formulations. Founded in 2007 and headquartered in London, United Kingdom, OKYO Pharma operates primarily in the United States and United Kingdom, with ordinary shares listed on NASDAQ (OKYO) targeting ophthalmology markets characterized by significant unmet needs such as the estimated $5 billion dry eye sector and conditions lacking FDA-approved therapies like neuropathic corneal pain. Recent developments include securing $1.9 million in non-dilutive funding post-positive Phase 2 results, FDA Fast Track designation for urcosimod, plans to accelerate clinical development including a 100-patient multi-center Phase 2 expansion and FDA meeting, official USAN assignment as urcosimod, presentations at BIO-Europe 2025 on trial updates where 75% of patients achieved over 80% pain reduction, and Executive Chairman Gabriele Cerrone increasing his stake to over 10.4 million shares through recent acquisitions by Panetta Partners Limited.
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OKYO Pharma Announces Purchase of Shares by Chairman
Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources
Disney streaming margins and parks business in focus ahead of earnings
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
Delta Air Lines earnings resilience supports valuation, Bank of America says
US bank earnings could surprise to the upside as Bank of America highlights strong operating backdrop
First Hawaiian pushes into California with TriCo Bancshares deal
TSMC reports record June revenue, second quarter sales top guidance
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
Forte Biosciences shares surge after positive phase 1b vitiligo results
FTSE 100 Live: Stocks called higher as Trump signals Iran ready for talks
Nasdaq bucks market selloff as US-Iran tensions push oil higher
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI